Bupa has developed regenerative medicine support for healthcare commissioners with the backing of the Department of Business, Innovation and Skills.
The decision-making toolkit has been two years in development and comes as healthcare commissioners work on the future role of regenerative medicine.
Healthcare commissioners are striving to avoid resources being used on expensive treatments with no important contribution to better patient outcomes.
Dr Virginia Warren, assistant medical director at Bupa UK, and leader of the development, said: "Given that some regenerative medicines will be costly, commissioners will want to see clinical evidence that an RM is more effective than the current care, or meets a currently-unmet need, as well as evidence of its safety and efficacy in the real world - not just a laboratory setting.
"The challenge for commissioners is how to make these decisions in a balanced way. No one wants poor value-for-money or patients disappointed by treatments that are not appropriate for them."
She added the aim of the toolkit was to help commissioners decide which medicines to make available.
Regenerative medicine covers a range of therapies that help organs and tissues to regrow, or support while they do.
A number of regenerative medicines are in development for both common and rare diseases with potential to greatly reduce burden of disease.
Examples of regenerative medicine in development include researchers in Berlin who are looking at a therapy which eases the pain of poor blood supply to the leg muscles, a condition often linked to diabetes.
In London researchers are looking into using cell treatments to alleviate the rare and painful condition of epidemolysis bullosa which causes the skin to blister extremely easily.
The toolkit has been openly published in The Journal of Regenerative Medicine.
